Drug recall · April 24, 2013
Suprax (cefixime for oral suspension) USP recall
Why: Discoloration; Product may not meet specifications for color description once reconstituted.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when reconstituted), Manufactured for Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Baltimore, MD 21202, Manufactured by Lupin Limited Mumbai 400 058 India, NDC 68180-202-03.
- Lots / codes
Lot #s: MSA 2021A, MSA 2024A, MSA 2025A, Exp July 2014
- Quantity
- 64,368 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Nationwide
- Initiated
- January 31, 2013 · Voluntary: Firm initiated
- Classified
- April 18, 2013
- Reported
- April 24, 2013
- Ended
- September 11, 2013
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefixime
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.